Objective
=========

To evaluate the clinical and functional activity of patients with rheumatoid arthritis at one and two years after starting anti-TNF therapy.

Patients and methods
====================

This is a retrospective study of 50 RA patients, who started ANTI-TNF theraphy between June 2006 and july 2009. The main variables in the study were: DAS28, HAQ and pain VAS. We analyzed evolution after 1 year and 2 years from the beginning of the treatment. The comparison with the basal state was made with Student's *t* test. The statistical study was analyzed by the SPSS 18,0.

Results
=======

The study includes 50 patients, 66% female, with RF in 76% and erosions in 64%, treated with etanercept (28), adalimumab (13) and infliximab (9). Most of them (70%) had recieved at least 2 FAMES before biological. In the below table we compare changes in clinical parameters for different biologics after one and two years.

                BASAL         12 MONTHS (p basal-12M)    24 MONTHS (p 12M-24M)
  ------------- ------------- -------------------------- ------------------------
  EVA (mm)                                               
  -Etanercept   72,21±16,78   33,20 ± 20,05 (p\<0,005)   31,95 ± 27,12 (p=0,39)
  -Adalimumab   69,83±20,54   45,00 ± 28,33 (p=0,21)     51,00 ± 28,44 (p=0,16)
  -Infliximab   69,78±15,45   42,56 ± 23,41 (p=0,015)    37,71 ± 23,95 (p=0,86)
                                                         
  DAS28                                                  
  -Etanercept   5,88 ± 1,05   2,85 ± 1,16 (p\<0,005)     3,09 ± 1,52 (p=0,98)
  -Adalimumab   5,73 ± 1,51   4,05 ± 2,43 (p=0,011)      3,90 ± 1,88 (p=0,22)
  -Infliximab   6,03 ± 1,87   4,08 ± 1,61 (p=0,021)      3,83 ± 1,66 (p=0,91)
                                                         
  HAQ                                                    
  -Etanercept   1,61 ± 0,61   0,77 ± 0,64 (p \<0,005)    0,80 ± 0,73 (p = 0,87)
  -Adalimumab   1,63 ± 0,58   1,35 ± 0,63 (p = 0,05)     1,38 ± 0,70 (p =0,58)
  -Infliximab   1,45 ± 0,74   1,24 ± 0,72 (p = 0,20)     1,28 ± 0,69 (p = 0,34)

Conclusions
===========

All anti-TNF significantly improve disease activity, functional status and pain VAS after the first year. This improvement continues but not significantly increases the second year.

Etanercept is the only drug with a significant reduction for HAQ, DAS28 and pain VAS.
